Biogen Inc. (BIIB)
Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug
Biogen's stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.
Biogen initiated with a Neutral at Citi
Citi analyst Geoff Meacham initiated coverage of Biogen with a Neutral rating and $190 price target. The company's strategy to offset core franchise erosion has been to develop assets with significant unmet need in very difficult indications, the analyst tells investors in a research note. The firm says Biogen's pipeline still looks to have higher clinical risk overall versus the company's big biotech peers, "but this also conveys significant option value."
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BIIB vs. MYGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors a better bang for their buck right now?
Are Investors Undervaluing Biogen (BIIB) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Biogen reported its Q3 earnings yesterday, October 30. Revenue of $2.5bn was reported and non-GAAP EPS of $4.08. Growth was generally flat or declining for many key assets, with the performance of AD drug Leqembi especially underwhelming.
Biogen Analysts Slash Their Forecasts After Q3 Results
Biogen Inc BIIB reported upbeat earnings for the third quarter on Wednesday.
Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.
Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q3 2024 Earnings Call Transcript October 30, 2024 8:30 AM ET Company Participants Stephen Amato - Senior Director of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Development Mike McDonnell - CFO Alisha Alaimo - Head & President of North America Conference Call Participants Brian Abrahams - RBC Capital Markets Phil Nadeau - TD Cowen Marc Goodman - Leerink Salveen Richter - Goldman Sachs Michael Yee - Jefferies Umer Raffat - Evercore ISI Jay Olson - Oppenheimer Evan Seigerman - BMO Capital Markets Paul Matteis - Stifel Terence Flynn - Morgan Stanley Operator Good morning. My name is Cynthia, and I will be your conference operator today.
Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.77 per share. This compares to earnings of $4.36 per share a year ago.
